Tepoditamab

Description

Tepoditamab MCLA-117 is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine IFN?, IL-6, IL-8, IL-10, and TNF? and IFN? release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia AML research.